Inventor · disambiguated record
Jieyi Wang
Also filed as: WANG JIEYI
22 granted patents·16 pending applications·404 citations·filing 1999–2023
95Inventor score
Files withABBOTT LAB9LYVGEN BIOPHARMA HOLDINGS LTD8ABBVIE INC6ABBVIE BIOTHERAPEUTICS INC2LYVGEN BIOPHARMA CO LTD2
Top patents by PatentIndex Score
38 records- 0195US11203643B2Humanized anti-CD137 antibodies and uses thereofLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2021·Granted Dec 21, 2021·11 cites·17 claims
- 0295US6323228B13-substituted indole angiogenesis inhibitorsABBOTT LAB·Filed 2000·Granted Nov 27, 2001·76 cites·30 claims
- 0394US9029508B2Dual variable domain immunoglobulins and uses thereofGHAYUR TARIQ·Filed 2009·Granted May 12, 2015·57 cites·22 claims
- 0494US7772231B2Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitorsABBOTT LAB·Filed 2006·Granted Aug 10, 2010·68 cites·20 claims
- 0594US7030262B23-Amino-2-hydroxyalkanoic acids and their prodrugsABBOTT LAB·Filed 2003·Granted Apr 18, 2006·42 cites·4 claims
- 0692US10383948B2Anti-cMet antibody drug conjugates and methods for their useABBVIE INC·Filed 2018·Granted Aug 20, 2019·10 cites·12 claims
- 0792US6887863B2Hydrazide and alkoxyamide angiogenesis inhibitorsABBOTT LAB·Filed 2004·Granted May 3, 2005·32 cites·40 claims
- 0890US7491718B2Sulfonamides having antiangiogenic and anticancer activityABBOTT LAB·Filed 2003·Granted Feb 17, 2009·35 cites·3 claims
- 0989US9725515B2Prolactin receptor binding proteins and uses thereofABBVIE INC·Filed 2013·Granted Aug 8, 2017·10 cites·50 claims
- 1088US10875921B2Anti-4-1BB antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Dec 29, 2020·4 cites·18 claims
- 1187US6242494B1Substituted β-amino acid inhibitors of methionine aminopeptidase-2ABBOTT LAB·Filed 1999·Granted Jun 5, 2001·47 cites·15 claims
- 1286US11186648B2Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereofLYVGEN BIOPHARMA CO LTD·Filed 2021·Granted Nov 30, 2021·2 cites·11 claims
- 1382US10913797B2Anti-PD-1 antibodies and therapeutic uses thereofLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2016·Granted Feb 9, 2021·3 cites·23 claims
- 1475US8354422B2Pyrimidine inhibitors of kinase activityABBOTT LAB·Filed 2010·Granted Jan 15, 2013·2 cites·18 claims
- 1574US8486933B2Pyrimidine inhibitors of kinase activityWANG GARY T·Filed 2010·Granted Jul 16, 2013·3 cites·22 claims
- 1672US10184003B2Prolactin receptor binding proteins and uses thereofABBVIE INC·Filed 2016·Granted Jan 22, 2019·1 cites·30 claims
- 1767US7495068B2Antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesisABBOTT LAB·Filed 2004·Granted Feb 24, 2009·1 cites·8 claims
- 1865US2021312797A9Prolactin receptor binding proteins and uses thereofABBVIE INC·Filed 2020·Application pending·0 cites
- 1959US2025388669A1Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulationWANG JIEYI·Filed 2023·Application pending·0 cites
- 2059US2022081487A1Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereofLYVGEN BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 2158US2019153110A1Prolactin receptor binding proteins and uses thereofABBVIE INC·Filed 2018·Application pending·0 cites
- 2258US2017348429A1ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2358US2024218069A1Bi-specific antibodies comprising anti-b7h3 binding moleculesLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2022·Application pending·0 cites
- 2456US2023406950A1Bi-specific antibodies comprising anti-cd137 binding moleculesLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2021·Application pending·0 cites
- 2555US12024560B2Therapeutic agents and methods for enhancing immune responses in tumor microenvironmentLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2018·Granted Jul 2, 2024·0 cites·5 claims
- 2651US11976123B2Anti-CD40 antibodies and uses thereofLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2019·Granted May 7, 2024·0 cites·17 claims
- 2751US2010260668A1Dual Variable Domain Immunoglobulins and Uses ThereofABBOTT LAB·Filed 2009·Application pending·0 cites
- 2851US2022372155A1Anti-cd40 binding molecules and bi-specific antibodies comprising suchLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2020·Application pending·0 cites
- 2951US2015104452A1Dual variable domain immunoglobulins and uses thereofABBVIE INC·Filed 2014·Application pending·0 cites
- 3048US8067409B2Protein kinase inhibitorsBA-MAUNG NWE Y·Filed 2008·Granted Nov 29, 2011·0 cites·12 claims
- 3144US11505615B2Anti-CD137 antibodies and uses thereofLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2018·Granted Nov 22, 2022·0 cites·11 claims
- 3244US2004077031A1Novel methionine aminopeptidase-2 and uses thereofFiled 2002·Application pending·0 cites
- 3342US2002002152A1Hydrazide and alkoxyamide angiogenesis inhibitorsFiled 2001·Application pending·0 cites
- 3438US2004068012A1Sulfonamides having antiangiogenic and anticancer activityFiled 2002·Application pending·0 cites
- 3537US2002091148A13-substituted indole antiproliferative angiogenesis inhibitorsFiled 2001·Application pending·0 cites
- 3637US2004157836A1Sulfonamides having antiangiogenic and anticancer activityFiled 2003·Application pending·0 cites
- 3735US8536180B2Pyrimidine inhibitors of kinase activityCLARK RICHARD F·Filed 2010·Granted Sep 17, 2013·0 cites·25 claims
- 3827US2002106775A1Highly crystalline urokinaseFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jieyi Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →